Evaluating drainage tube removal after stomach surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine if removing a drainage tube before discharge affects the rate of intra-abdominal complications in patients who have undergone gastrectomy for gastric cancer. It is an open-label randomized controlled trial involving 60 patients, who will be divided into two groups: one will keep the drainage tube while the other will have it removed. The primary focus is on the incidence of complications within one month post-surgery, specifically for those with high postoperative drainage. Eligible participants must have a diagnosis of gastric adenocarcinoma and meet specific postoperative drainage criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients pathologically diagnosed with gastric adenocarcinoma before surgery.
* Patients eligible for complete surgical resection (R0 resection).
* Patients with an ASA (American Society of Anesthesiologists) score of 3 or lower.
* Patients with more than 300 ml of drainage in the 24 hours on the postoperative day 4.

Exclusion Criteria:

* Patients aged 80 or older.
* Patients with stage IV gastric cancer.
* Patients with ascites due to peritoneal metastasis.
* Patients with evident intra-abdominal complications following surgery.
* Patients who require the insertion of additional percutaneous drainage due to insufficient drainage.
* Patients who underwent incomplete gastric resection (R1 or R2 resection).
* Patients diagnosed with cancers other than gastric cancer.
* Patients with a history of major intra-abdominal surgery or abdominal radiotherapy that may hinder the normal absorption of intra-abdominal fluid.
* Patients with more than 500 ml of drainage in the 24 hours on postoperative day 4.
* Patients presenting with any of the following clinical signs or diagnoses:

  1. Postoperative pancreatic fistula (POPF), defined as drain amylase levels (Drain amylase; D-amy) more than 3 times higher than serum amylase levels (Serum amylase; S-amy).
  2. Fever exceeding 37.8℃.
  3. Presence of any of the following clinical markers of inflammation:

     i. White blood cell count (WBC) \> 15,000/μL ii. C-reactive protein \> 200 mg/L
  4. Observation of non-serous drainage fluid, such as:

     i. Chylous fluid: Milky-colored fluid. ii. Bloody or sanguineous fluid: Intra-abdominal fluid suggestive of ongoing hemorrhage.
* Vulnerable subjects will not be enrolled in the study, including minors, pregnant women, neonates, adults with impaired consent capacity, individuals in institutional facilities, students, employees of medical institutions or research centers, pharmaceutical company employees, military personnel, unemployed persons, impoverished individuals, homeless individuals, terminally ill patients, or patients in emergency situations.

Where it's running

• Gangnam Severacne Hospital Yonsei University College of Medicine
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: In-Kyu Kwon
• Email: gsirb@yuhs.ac
• Phone: 82-2-2019-4601

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.